He has received research funding from Medtronic and is a participant in a speakers bureau for Abbott, Ascensia, Bioton, Boehringer Ingelheim, Eli Lilly, Medtronic, Novo Nordisk, Roche, Sanofi and Servier
Heres a birds-eye view: Sign up
Results tend to be better when the medication is combined with support for eating patterns, activity and sleep
Some researchers believe those who have a goal for more significant weight loss may be relatively better candidates for prescription weight loss drugs compared to those with more modest weight loss goals
GLP-1 is the hormone responsible for inhibiting the production of glucagon and promoting the production of insulin
Among the various HFpEF phenotypes identified, the obesity-related phenotype characterized by visceral adiposity and insulin resistance appears to be the most prevalent (92)